tradingkey.logo

Nuwellis Inc

NUWE
查看詳細走勢圖
2.160USD
0.000
收盤 12/19, 16:00美東報價延遲15分鐘
2.95M總市值
0.01本益比TTM

Nuwellis Inc

2.160
0.000
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

-5.26%

1月

-4.85%

6月

-81.56%

今年開始到現在

-95.37%

1年

-94.91%

查看詳細走勢圖

TradingKey Nuwellis Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Nuwellis Inc當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名154/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價11.00。中期看,股價處於下降通道。近一個月,市場表現較強,但基本面和技術面綜合得分較低,較強的走勢沒有得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Nuwellis Inc評分

相關信息

行業排名
154 / 208
全市場排名
438 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 1 分析師
持有
評級
11.000
目標均價
+4890.93%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Nuwellis Inc亮點

亮點風險
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
業績增長期
公司處於發展階段,最新年度總收入8.74M美元
估值高估
公司最新PE估值0.01,處於3年歷史高位
機構加倉
最新機構持股13.52K股,環比增加42.73%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉31.00股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.99

Nuwellis Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Nuwellis Inc簡介

Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
公司代碼NUWE
公司Nuwellis Inc
CEOErb (John L)
網址https://www.nuwellis.com/

常見問題

Nuwellis Inc(NUWE)的當前股價是多少?

Nuwellis Inc(NUWE)的當前股價是 2.160。

Nuwellis Inc 的股票代碼是什麼?

Nuwellis Inc的股票代碼是NUWE。

Nuwellis Inc股票的52週最高點是多少?

Nuwellis Inc股票的52週最高點是70.140。

Nuwellis Inc股票的52週最低點是多少?

Nuwellis Inc股票的52週最低點是2.020。

Nuwellis Inc的市值是多少?

Nuwellis Inc的市值是2.95M。

Nuwellis Inc的淨利潤是多少?

Nuwellis Inc的淨利潤為-10.62M。

現在Nuwellis Inc(NUWE)的股票是買入、持有還是賣出?

根據分析師評級,Nuwellis Inc(NUWE)的總體評級為持有,目標價格為11.000。

Nuwellis Inc(NUWE)股票的每股收益(EPS TTM)是多少

Nuwellis Inc(NUWE)股票的每股收益(EPS TTM)是218.667。
KeyAI